Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Efficacy of Corneal Cross Linking for the Treatment of Myopia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent~* Willingness to follow all instructions and comply with schedule for follow up visits~* Having myopia with manifest refraction spherical equivalent of -1.00 to -2.50 D, with cylindrical component pl to -0.75 D~* Social security insurance or equivalent~Exclusion Criteria:~* sensitivity to the use of the test article(s)~* hypersensitivity to local anesthesics~* Corneal pachymetry that is \< 480 microns~* Eyes with keratoconus~* Eyes which are aphakic or with corneal intacs~* Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example: History of corneal disease (e.g., herpes simplex, recurrent erosion syndrome, corneal dystrophy, refractive keratotomy etc.), clinically significant corneal scarring in the crosslinking treatment zone~* Pregnancy or lactation~* Patients with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing~* Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.~* Juridical protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corneal cross linking (CXL) (Type: EXPERIMENTAL): Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.

Based on this trial design, predict the completion outcome and termination type (if applicable).